Global Leukemia Therapeutics Market 2016-2020

Global leukemia therapeutics market forecasts

According to the leukemia therapeutics industry insights at Technavio, the leukemia therapeutics market will witness fast-paced growth and will post a staggering CAGR of more than 8% over the forecast period. The application for expanded indication approvals is one of the primary factors driving the growth of this market. The concept of repositioning came into practice in the early 1990s and is based on the possibility that different diseases could be sharing common molecular pathways. This has led several companies to conduct clinical trials to determine the effectiveness of the drugs in all such related indications. As this process of drug re-positioning leading to extended indication is a low-risk, high-reward strategy, it could increase the scope of treatment and help in increased market penetration.

One of the recent leukemia therapeutics market trends propelling the growth prospects for this market is the rise in the development of combination therapies to treat leukemia. Combination therapies for the treatment of leukemia are mostly available in the form of combination chemotherapy drugs. Some of the approved combinations include chlorambucil with prednisone, and cyclophosphamide with vincristine and prednisone for the treatment of chronic lymphocytic leukemia (CLL); a combination of cytarabine, daunorubicin, and etoposide for the treatment of acute myeloid leukemia (AML); and a combination of hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone for the treatment of acute lymphocytic leukemia (ALL). These therapies are expected to increase the effectiveness of the treatment, which in turn, will increase the patient compliance toward the use of these drugs.

Competitive landscape and key vendors

The leukemia therapeutics market characterized by the presence of several well-established vendors. The market is growing steadily because of an augmented demand for leukemia drugs, which is also expected to boost R&D activities. The vendors are manufacturing and selling drugs that can effectively treat the disease, and also possess a high efficacy and safety profile. This is expected to help the vendors to gain a competitive edge over their peers.

 Key vendors in this market are 

• F. Hoffmann-La Roche
• Novartis
• Bristol-Myers Squibb
• AbbVie
• Teva Pharmaceuticals

Other prominent vendors in the market include Altor BioScience, Ambit BioSciences, Amgen, Ariad Pharmaceuticals, Arno Therapeutics, Astex Pharmaceuticals, AstraZeneca, Baxter Healthcare, Bayer HealthCare, Bellicum Pharmaceuticals, Biogen, Boehringer Ingelheim, BioLineRx, Boston Biomedical, Celator Pharmaceuticals, Celgene Corporation, CTI Biopharma, Chroma Therapeutics, Chugai Pharmaceutical, Cyclacel Pharmaceuticals, Daiichi Sankyo, Eisai, Emergent BioSolutions, Erytech Pharma, Fate Therapeutics, Genzyme Corp, Gilead Sciences, GlaxoSmithKline, iDD biotech, Immune Pharmaceuticals, Immunomedics, Infinity Pharmaceuticals, Innate Pharma, Jazz Pharmaceuticals, Juno Therapeutics, Karyopharm Therapeutics, Ligand Pharmaceuticals, Meda, MedImmune, Merck, Midas Pharmaceuticals, Molecular Templates, MorphoSys, Nippon Shinyaku, Novo Nordisk, Onconova Therapeutics, Ono Pharmaceuticals, Orphan Europe, Otsuka, Pfizer, Portola Pharmaceuticals, Regeneron Pharmaceuticals, Sanofi, Sigma-Tau Pharmaceuticals, Stemline Therapeutics, Sunesis Pharmaceuticals, TG Therapeutics, TheraMAB, Tolero Pharmaceuticals, XEME Biopharma, Xencor, and ZIOPHARM Oncology.

Segmentation by disease type and analysis of the leukemia therapeutics market  

• ALL
• CML
• CLL
• AML

The global CML therapeutics segment is one of the fastest growing segments of the market and is expected to reach over USD 5 billion by 2020. Factors such as the increasing use of combination therapies and the introduction of several breakthrough drugs in the market will drive this segment’s growth in the coming years.

Geographical segmentation and analysis of the leukemia therapeutics market 

• Americas
• APAC
• EMEA

In terms of geography, the Americas led the leukemia therapeutics market and is anticipated to reach close to USD 7 billion in 2020. The US is the largest revenue contributor in the region. The growth of this market in the region is attributed to the high prevalence of the disease in the region. According to several research studies, nearly 61,000 new cases of leukemia will be diagnosed in the US in 2016, of which 20,000 cases will be of AML. Furthermore, the presence of patient assistance programs by government and non-government organizations in the US are also expected to drive market growth. As drugs such as Iclusig, Rituxan, and Arzerra are costly, patient withdrawal from the treatment regimen is common. Instead, end-users prefer affordable generic medication such as generic imatinib. However, the availability of patient assistance programs from vendors and other government and non-government organizations will help decrease non-compliance among individuals and increase the demand for branded TKIs.

Key questions answered in the report include

• What will the market size and the growth rate be in 2020?
• What are the key factors driving the leukemia therapeutics market?
• What are the key market trends impacting the growth of the leukemia therapeutics market?
• What are the challenges to market growth?
• Who are the key vendors in the leukemia therapeutics market?
• What are the market opportunities and threats faced by the vendors in the leukemia therapeutics market?
• What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
• What are the key outcomes of the five forces analysis of the leukemia therapeutics market?

Technavio also offers customization on reports based on specific client requirement.

Related reports:

• Global Chronic Lymphocytic Leukemia Therapeutics Market 2016-2020
• Global Acute Lymphocytic Leukemia Market 2015-2019
• Global Cancer Diagnostic Devices Market 2016-2020
• Global Cancer Pain Therapeutics Market 2015-2019
• Global Cancer Immunotherapies Market 2016-2020